NASDAQ · Drug Manufacturers - Specialty & Generic

Embecta Corp. (EMBC) Stock

$3.46 +5.17% NASDAQ: EMBC Healthcare

Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes.

Valuation

MetricValue
Price$3.46
Market Cap$205.27M
P/E Ratio1.72
P/B Ratio-0.31
P/S Ratio0.19
EPS (TTM)$1.62
52-Week High$15.55
52-Week Low$2.77
Dividend Yield1.22%

Financials & Margins

MetricValue
ROE-17.48%
ROA10.87%
ROCE39.71%
Gross Margin30.46%
Operating Margin30.46%
Net Margin10.73%
Debt/Equity-2.17
Current Ratio2.41

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.2B$1.1B$1.1B$1.1B$1.1B
Operating Profit$492.0M$378.0M$230.0M$174.0M$329.0M
Net Profit$415.0M$224.0M$70.0M$78.0M$95.0M
EPS$7.31$3.89$1.22$1.34$1.62
Op Margin42.2%33.5%20.5%15.5%30.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$788.0M$1.1B$1.2B$1.3B$1.1B
Total Liabilities$194.0M$2.0B$2.0B$2.0B$1.7B
Cash$0$331.0M$326.0M$268.0M$226.0M
Borrowings$4.0M$1.6B$1.6B$1.6B$1.4B

Latest News

Embecta (EMBC) Stock Fair Value Moves Lower As Analysts Reset Medtech Expectations Simply Wall St. · Jul 15, 2026 embecta appoints Nimish Muzumdar as SVP and President, North America GlobeNewswire · Jun 16, 2026 Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire · Jun 5, 2026 embecta to Participate in Investor Events GlobeNewswire · Jun 1, 2026 Embecta (EMBC) Hit With A Sharp Target Cut As Medtech Sentiment Weakens Insider Monkey · May 24, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$456.0M$412.0M$68.0M$36.0M$192.0M
Investing Cash Flow$-78.0M$-48.0M$-53.0M$-32.0M$-19.0M
Financing Cash Flow$-417.0M$-1.5B$-4.0M$-3.0M$-6.0M
Net Cash Flow$0$331.0M$-4.0M$-52.0M$-46.0M
Free Cash Flow$417.0M$388.0M$41.0M$20.0M$182.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA3.71
FCF Yield88.66%
Quick Ratio1.73
Interest Coverage3.07
Return 1Y-68.86%
Return 3Y-83.58%
Return 5Y—

Ownership

Insiders Held1.74%
Institutions Held100.57%
Institutions Float Held102.35%
Institutional HolderSharesReport Date
Blackrock Inc.9,167,2122026-03-31
Yacktman Asset Management Lp3,671,8772026-03-31
River Road Asset Management, LLC3,449,5022026-03-31
American Century Companies Inc3,439,5122026-03-31
Vanguard Capital Management LLC2,563,9512026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AQST $3.60 -4.26% -6.11 $451.68M 0.00%
CDNA $43.71 +14.72% 18.87 $2.26B 0.00%
EBS $7.16 -1.45% 8.67 $369.17M 0.00%
EVH $3.04 -4.56% -0.77 $341.38M 0.00%
MRVI $6.90 +3.06% -4.48 $1.90B 0.00%

About Embecta Corp.

Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.

Embecta Corp. is led by CEO Devdatt Kurdikar, employs 2,000 people, headquartered in US, publicly traded since 2022.

Embecta Corp. (EMBC) stock trades at $3.46 with a market capitalization of $205.27M. The stock is valued at a price-to-earnings (P/E) ratio of 1.72, price-to-book of -0.31, price-to-sales of 0.19. Over the past 52 weeks the stock has ranged between $2.77 and $15.55, and currently trades 77.7% below its 52-week high. It pays a dividend yielding 1.22%.

On profitability, Embecta Corp. generates a return on equity (ROE) of -17.48%, return on capital employed of 39.71%, an operating margin of 30.46%, a net profit margin of 10.73%.

Official website: www.embecta.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides